Colorcon launches Colorcon Academy
Industry leading further education programs unified and expanded.
Colorcon has launched the Colorcon Academy, an exciting new entity to build on the success of the company's highly valued education programs worldwide. Colorcon has provided speciality excipients for pharmaceutical and nutraceutical applications for nearly 60 years, and has always placed great emphasis to help customers optimize formulation development and manufacturing processes through its education events. The company's goal is to help clients achieve both outstanding technical and business outcomes.
Dr Ali Rajabi-Siahboomi, VP/Chief Scientific Officer, Colorcon said: “At Colorcon we are always striving to do something extra. This year, with the introduction of the Colorcon Academy, we’ve reorganized our highly valued education programs to advance our global standard in education. Under the new Colorcon Academy platform, we will offer the different programs at our 20 technical services facilities worldwide, in addition to events designed specifically for our customers, which are held at their site. Academy attendees have the opportunity to progress their skills in pharmaceutical sciences and become leaders in their own organizations at locations convenient to them.
"Since the first Colorcon Coating School in the 1980s, we have provided continuing education to thousands of customers around the world each year and continue to strengthen our commitment to advancing pharmaceutical technology and it’s applications.
"The Colorcon Academy program is designed to give pharmaceutical professionals a deeper knowledge of excipient functionality, core formulation, film coating and controlled release of oral solid dosage forms, along with regulatory insights; plus the opportunity to explore innovative solutions to formulation challenges.
"The thousands of course attendees have ranged from senior research scientists, to technology transfer scientists and process engineers. We receive very positive feedback from attendees and their managers, and continue to update and extend the content of the courses in line with changing industry needs. I am personally committed to the educational advances we provide and trust we continue to surpass attendees’ expectations with the launch of the Colorcon Academy,” concluded Dr Rajabi-Siahboomi.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.